دورية أكاديمية
أعرض في EDS

Effects of therapeutic vaccination on the control of SIV in rhesus macaques with variable responsiveness to antiretroviral drugs.

التفاصيل البيبلوغرافية
العنوان: Effects of therapeutic vaccination on the control of SIV in rhesus macaques with variable responsiveness to antiretroviral drugs.
المؤلفون: Tunggal HC; Department of Microbiology, University of Washington, Seattle, Washington, United States of America.; Washington National Primate Research Center, Seattle, Washington, United States of America., Munson PV; Department of Microbiology, University of Washington, Seattle, Washington, United States of America.; Washington National Primate Research Center, Seattle, Washington, United States of America., O'Connor MA; Department of Microbiology, University of Washington, Seattle, Washington, United States of America.; Washington National Primate Research Center, Seattle, Washington, United States of America., Hajari N; Washington National Primate Research Center, Seattle, Washington, United States of America., Dross SE; Department of Microbiology, University of Washington, Seattle, Washington, United States of America.; Washington National Primate Research Center, Seattle, Washington, United States of America., Bratt D; Washington National Primate Research Center, Seattle, Washington, United States of America., Fuller JT; Department of Microbiology, University of Washington, Seattle, Washington, United States of America., Bagley K; Profectus Biosciences, Baltimore, Maryland, United States of America., Fuller DH; Department of Microbiology, University of Washington, Seattle, Washington, United States of America.; Washington National Primate Research Center, Seattle, Washington, United States of America.
المصدر: PloS one [PLoS One] 2021 Jun 17; Vol. 16 (6), pp. e0253265. Date of Electronic Publication: 2021 Jun 17 (Print Publication: 2021).
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
أسماء مطبوعة: Original Publication: San Francisco, CA : Public Library of Science
مواضيع طبية MeSH: Anti-Retroviral Agents/*therapeutic use , Simian Acquired Immunodeficiency Syndrome/*prevention & control , Simian Immunodeficiency Virus/*immunology , Vaccines, DNA/*therapeutic use, Animals ; Macaca mulatta ; Simian Acquired Immunodeficiency Syndrome/drug therapy ; Simian Acquired Immunodeficiency Syndrome/immunology ; T-Lymphocytes/drug effects ; T-Lymphocytes/immunology
مستخلص: A therapeutic vaccine that induces lasting control of HIV infection could eliminate the need for lifelong adherence to antiretroviral therapy. This study investigated a therapeutic DNA vaccine delivered with a single adjuvant or a novel combination of adjuvants to augment T cell immunity in the blood and gut-associated lymphoid tissue in SIV-infected rhesus macaques. Animals that received DNA vaccines expressing SIV proteins, combined with plasmids expressing adjuvants designed to increase peripheral and mucosal T cell responses, including the catalytic subunit of the E. coli heat-labile enterotoxin, IL-12, IL-33, retinaldehyde dehydrogenase 2, soluble PD-1 and soluble CD80, were compared to mock-vaccinated controls. Following treatment interruption, macaques exhibited variable levels of viral rebound, with four animals from the vaccinated groups and one animal from the control group controlling virus at median levels of 103 RNA copies/ml or lower (controllers) and nine animals, among all groups, exhibiting immediate viral rebound and median viral loads greater than 103 RNA copies/ml (non-controllers). Although there was no significant difference between the vaccinated and control groups in protection from viral rebound, the variable virological outcomes during treatment interruption enabled an examination of immune correlates of viral replication in controllers versus non-controllers regardless of vaccination status. Lower viral burden in controllers correlated with increased polyfunctional SIV-specific CD8+ T cells in mesenteric lymph nodes and blood prior to and during treatment interruption. Notably, higher frequencies of colonic CD4+ T cells and lower Th17/Treg ratios prior to infection in controllers correlated with improved responses to ART and control of viral rebound. These results indicate that mucosal immune responses, present prior to infection, can influence efficacy of antiretroviral therapy and the outcome of immunotherapeutic vaccination, suggesting that therapies capable of modulating host mucosal responses may be needed to achieve HIV cure.
Competing Interests: Dr. Kenneth Bagley was a paid employee of Profectus Biosciences and had stock options with Profectus when the research was performed. A portion of this study was supported by the SBIR R44AI110315 awarded to Profectus BioSciences. Dr. Bagley was the Principal Investigator for R44AI110315. At the time the study was performed, Dr. Bagley had unexercised stock options with with Profectus BioSciences. Dr. Bagley left Profectus BioSciences in August 2019. He did not exercise any stock options and no longer has an interest in Profectus BioSciences. Dr. Kenneth Bagley is currently a paid employee of Orlance Incorporated, which was co-founded by D.H.F. This study was not supported in any way by Orlance. The affiliations of Dr. Bagley with Profectus and Orlance and Dr. Fuller’s co-founder interests in Orlance do not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patent applications (pending or actual) affiliated with this study.
References: PLoS One. 2012;7(3):e33715. (PMID: 22442716)
Infect Immun. 2002 Oct;70(10):5533-9. (PMID: 12228279)
Mol Aspects Med. 2012 Feb;33(1):63-76. (PMID: 22120429)
Front Immunol. 2014 Sep 08;5:417. (PMID: 25250026)
Hum Vaccin Immunother. 2015;11(9):2228-40. (PMID: 26042527)
Nat Med. 2006 Dec;12(12):1365-71. (PMID: 17115046)
Retrovirology. 2010 Mar 16;7:21. (PMID: 20233398)
Med Care. 2006 Nov;44(11):990-7. (PMID: 17063130)
Sci Transl Med. 2012 Feb 29;4(123):123ra25. (PMID: 22378925)
Sci Rep. 2020 Jul 9;10(1):11394. (PMID: 32647227)
Sci Transl Med. 2013 Jan 2;5(166):166ra2. (PMID: 23283367)
Lancet Infect Dis. 2014 Apr;14(4):291-300. (PMID: 24525316)
J Virol. 1995 Dec;69(12):7982-90. (PMID: 7494311)
Nature. 2011 May 26;473(7348):523-7. (PMID: 21562493)
AIDS Res Hum Retroviruses. 2008 Aug;24(8):1103-16. (PMID: 18620495)
Eur J Immunol. 2011 Nov;41(11):3351-60. (PMID: 21887788)
J Infect Dis. 2013 Sep 1;208(5):818-29. (PMID: 23840043)
Eur J Immunol. 2018 Jun;48(6):898-914. (PMID: 29427516)
J Med Primatol. 2013 Oct;42(5):237-46. (PMID: 24025078)
J Virol. 2010 Oct;84(19):10354-65. (PMID: 20668079)
PLoS One. 2012;7(1):e29231. (PMID: 22242162)
PLoS Pathog. 2013;9(7):e1003471. (PMID: 23853592)
Vaccine. 2016 Apr 27;34(19):2225-32. (PMID: 27002500)
Blood. 2006 Dec 1;108(12):3834-42. (PMID: 16896154)
PLoS Pathog. 2010 Jan 22;6(1):e1000738. (PMID: 20107597)
Nature. 2016 Dec 8;540(7632):284-287. (PMID: 27841870)
J Immunol. 2019 Feb 1;202(3):943-955. (PMID: 30635396)
AIDS. 2017 Aug 24;31(13):1819-1824. (PMID: 28692537)
J Virol. 2020 Jul 1;94(14):. (PMID: 32350073)
J Virol. 2011 Sep;85(18):9578-87. (PMID: 21734035)
Blood. 2013 Jan 3;121(1):29-37. (PMID: 23043072)
Hum Vaccin Immunother. 2012 Nov 1;8(11):1620-9. (PMID: 22894956)
Nat Med. 2007 Jan;13(1):46-53. (PMID: 17173051)
J Virol. 2002 Apr;76(7):3309-17. (PMID: 11884556)
Sci Transl Med. 2017 Dec 6;9(419):. (PMID: 29212716)
Nature. 2014 Aug 7;512(7512):74-7. (PMID: 25042999)
Retrovirology. 2016 Apr 01;13:21. (PMID: 27036656)
Infect Dis Clin North Am. 2014 Sep;28(3):371-402. (PMID: 25151562)
Viruses. 2019 Feb 27;11(3):. (PMID: 30818749)
Curr Opin HIV AIDS. 2010 Mar;5(2):151-7. (PMID: 20543593)
J Exp Med. 2004 Sep 20;200(6):749-59. (PMID: 15365096)
Hum Vaccin Immunother. 2018 Jul 3;14(7):1820-1831. (PMID: 29648490)
J Clin Invest. 2020 Feb 3;130(2):789-798. (PMID: 31661461)
J Virol. 2021 Feb 24;95(6):. (PMID: 33408173)
Nature. 2009 Mar 12;458(7235):206-10. (PMID: 19078956)
Top HIV Med. 2007 Aug-Sep;15(4):114-7. (PMID: 17720995)
AIDS Res Hum Retroviruses. 2019 Mar;35(3):295-305. (PMID: 30398361)
Sci Transl Med. 2011 May 4;3(81):81ra36. (PMID: 21543722)
J Virol. 2013 Jul;87(13):7445-62. (PMID: 23616666)
Springer Semin Immunopathol. 2006 Nov;28(3):209-19. (PMID: 16932955)
Sci Immunol. 2018 Jun 1;3(24):. (PMID: 29858286)
NPJ Vaccines. 2020 May 8;5(1):36. (PMID: 32411399)
Cell. 2013 Oct 24;155(3):540-51. (PMID: 24243014)
PLoS Pathog. 2013 Mar;9(3):e1003211. (PMID: 23516360)
Blood. 2008 Oct 1;112(7):2826-35. (PMID: 18664624)
Vaccine. 2015 Aug 20;33(35):4313-20. (PMID: 25887087)
J Infect Dis. 2010 Jun 15;201(12):1788-95. (PMID: 20446848)
J Virol. 2012 Apr;86(7):3667-74. (PMID: 22278254)
J Virol. 2007 Aug;81(16):8827-32. (PMID: 17537848)
Science. 2012 Feb 24;335(6071):984-9. (PMID: 22323740)
PLoS Genet. 2010 Jun 24;6(6):e1000997. (PMID: 20585621)
AIDS. 2014 Mar 13;28(5):699-708. (PMID: 24549145)
J Virol. 2003 Feb;77(4):2736-40. (PMID: 12552014)
Virology. 2006 Apr 25;348(1):200-15. (PMID: 16439000)
Mucosal Immunol. 2008 Jul;1(4):279-88. (PMID: 19079189)
J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):445-9. (PMID: 11744832)
J Virol. 2006 May;80(10):5074-7. (PMID: 16641299)
Science. 1998 Apr 17;280(5362):427-31. (PMID: 9545219)
Curr HIV Res. 2019;17(2):75-84. (PMID: 31210114)
Vaccine. 2016 Nov 4;34(46):5629-5635. (PMID: 27670072)
J Immunol. 2002 Nov 1;169(9):5347-57. (PMID: 12391256)
J Exp Med. 2004 Sep 20;200(6):761-70. (PMID: 15365095)
Curr Opin HIV AIDS. 2018 Mar;13(2):119-127. (PMID: 29329113)
معلومات مُعتمدة: P51 OD010425 United States OD NIH HHS; T32 AI007140 United States AI NIAID NIH HHS; R44 AI110315 United States AI NIAID NIH HHS; R01 AI104679 United States AI NIAID NIH HHS; P30 AI027757 United States AI NIAID NIH HHS
المشرفين على المادة: 0 (Anti-Retroviral Agents)
0 (Vaccines, DNA)
تواريخ الأحداث: Date Created: 20210617 Date Completed: 20211116 Latest Revision: 20220311
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC8211199
DOI: 10.1371/journal.pone.0253265
PMID: 34138927
قاعدة البيانات: MEDLINE
الوصف
تدمد:1932-6203
DOI:10.1371/journal.pone.0253265